Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
IBIO > SEC Filings for IBIO > Form 8-K on 18-Sep-2013All Recent SEC Filings

Show all filings for IBIO, INC.

Form 8-K for IBIO, INC.


18-Sep-2013

Entry into a Material Definitive Agreement


Item 1.01 Entry into a Material Definitive Agreement

Amendment of TTA between iBio and Fraunhofer

We and Fraunhofer, USA, Inc. ("Fraunhofer"), our collaborative research and development partner, entered into a new agreement effective June 30, 2013 (the "2013 Amendment") that has the effect of further amending the terms of the Technology Transfer Agreement which we and Fraunhofer originally entered into effective as of January 1, 2004 (as previously amended, the "TTA"). The 2013 Amendment, which is intended to better align the mutual interests of iBio and Fraunhofer, has the following effects:

Our liabilities to Fraunhofer in the amount of approximately $2,863,000 as of June 30, 2013 were released and terminated.

The term of the TTA was extended by one year and will now expire on December 31, 2015.

Our obligation under the TTA, prior to the 2013 Amendment, to make three further time-based $1,000,000 payments, on April 2 and November 2, 2013 and April 2, 2014 ("Guaranteed Annual Payments") was terminated and replaced with an obligation to engage Fraunhofer in iBio selected and directed project specific development activities, priced according to a mutually-agreed fair market formula, in an aggregate amount not less than $3,000,000 prior to December 31, 2015. We believe that our right to select and direct specific projects will improve the efficiency of our product development activities and that the extension of the period over which this commitment must be fulfilled will enhance our ability to manage our cash outflow.

We terminated and released Fraunhofer from the obligation to make further financial contributions toward the enhancement, improvement and expansion of our technology in an amount at least equal to the Guaranteed Annual Payments, because we believe our technology development phase is completed and now are focusing on product development. Additionally, we terminated and released Fraunhofer from the obligation to further reimburse us for certain past and future patent related expenses.

Our obligation to remit to Fraunhofer minimum annual payments in the amount of $200,000 was terminated. Instead we will be obligated to remit royalties to Fraunhofer only on technology license revenues that we actually receive and on revenues from actual sales by us of products derived from our technology until the later of November 2023 or until such time as the aggregate royalty payments total at least $4,000,000.

The rate at which we will be obligated to pay royalties to Fraunhofer on iBioLaunch and iBioModulator license revenues we receive was reduced from 15% to 10%.

Any and all other claims of each party to any other amounts due at June 30, 2013 were mutually released.

  Add IBIO to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for IBIO - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.